Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Karen Anderson Sells 120,029 Shares

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Karen Anderson sold 120,029 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.25, for a total value of $3,150,761.25. Following the sale, the insider directly owned 62,085 shares of the company’s stock, valued at $1,629,731.25. This represents a 65.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA opened at $26.33 on Friday. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $9.60 and a one year high of $30.58. The company has a market cap of $3.85 billion, a P/E ratio of -14.39 and a beta of 1.55. The firm’s fifty day moving average price is $24.69 and its two-hundred day moving average price is $24.24. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57.

Wall Street Analysts Forecast Growth

CNTA has been the topic of a number of research reports. Guggenheim upped their price target on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Wolfe Research began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Finally, Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a report on Friday, January 16th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $39.80.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd bought a new stake in Centessa Pharmaceuticals in the 4th quarter valued at about $80,000. T. Rowe Price Investment Management Inc. increased its holdings in shares of Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after purchasing an additional 1,516 shares during the period. Coastal Bridge Advisors LLC raised its position in shares of Centessa Pharmaceuticals by 7.1% in the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock valued at $351,000 after buying an additional 931 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $1,978,000. Finally, Voloridge Investment Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $8,710,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.